ArticleERJ open research2023
Distribution of type 2 biomarkers and association with severity, clinical characteristics and comorbidities in the BREATHE real-life asthma population.
Article in ERJ open research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Fractional exhaled nitric oxide and blood eosinophils in relation to lung function, allergy and nasal polyps in asthma.The journal of allergy and clinical immunology. Global · 2026Article
- Article
- Integrative multi-omics reveals that downregulation of HLA-DPA1/DPB1 drives macrophage immune-metabolic dysregulation in pediatric asthma.Frontiers in immunology · 2026Article
- Biomarker-Defined Endotypes and Clinical Phenotypes of Asthma: A Cluster-Based Analysis of Type-2 Inflammatory Patterns and Their Clinical Correlates.Journal of asthma and allergy · 2026Article
- A practical approach to handling missing sputum samples in airway disease research.ERJ open research · 2025Article
- The Role of Endobronchial Biopsies in Evaluating Biologic Therapy Response in Severe Asthma.International journal of molecular sciences · 2025Review
- STING-dependent induction of neutrophilic asthma exacerbation in response to house dust mite.Allergy · 2025Article
- Eosinophil-Driven vs. Eosinophil-Associated Severe Asthma: Practical Implications for Target Treatment.International journal of molecular sciences · 2025Review
- Subtype prevalence and treatment implication in adolescents and adults with mild-to-moderate asthma: Systematic review and meta-analysis.The journal of allergy and clinical immunology. Global · 2025Article
- T2-low severe asthma clinical spectrum and impact: The Greek PHOLLOW cross-sectional study.Clinical and translational allergy · 2025Article
- Airways Type-2 Related Disorders: Multiorgan, Systemic or Syndemic Disease?International journal of molecular sciences · 2024Review
- Reliability of Total Serum IgE Levels to Define Type 2 High and Low Asthma Phenotypes.Journal of clinical medicine · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 2 (T2) high asthma is recognised as a heterogenous entity consisting of several endotypes; however, the prevalence and distribution of the T2 biomarkers in the general asthma population, across asthma severity, and across compartments is largely unknown. The objective of the present study was to describe expression and overlaps of airway and systemic T2 biomarkers in a clinically representative asthma population. Methods: Patients with asthma from the real-life BREATHE cohort referred to a specialist centre were included and grouped according to T2 biomarkers: blood and sputum eosinophilia (≥0.3×10 Results: Patients with mild-to-moderate asthma were younger (41 Conclusion: Severe asthma is more commonly associated with activation of several T2 pathways, indicating that treatments targeting severe asthma may need to act more broadly on T2 inflammatory pathways. Implementation of airway inflammometry in clinical care is of paramount importance, as the best treatable trait is otherwise is overlooked in a large proportion of patients irrespective of disease severity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.